In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death
Athanasios Vassilopoulos, Eleftherios Mylonakis
Abstract
SOURCE CITATION: N Engl J Med. 2022;386:1397-408. 35172054.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)RitonavirDisease2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PandemicIntensive care medicineInternal medicineEmergency medicineVirologyOutbreakHuman immunodeficiency virus (HIV)Infectious disease (medical specialty)Antiretroviral therapyViral loadCOVID-19 Clinical Research StudiesHematological disorders and diagnosticsSARS-CoV-2 and COVID-19 Research